Key Takeaways
- • Israel Englander's Millennium Management more than doubled its positions in AbbVie (NYSE: ABBV) and Costco (NASDAQ: COST) during Q2 2026, signaling conviction in both dividend-paying equities.
- • AbbVie's core pharmaceutical business remains solid despite historical patent cliff challenges, with immunology medicines Skyrizi and Rinvoq driving Q2 revenue growth of 10.2% year-over-year to approximately $17 billion; neither drug faces patent expiration until the next decade.
- • AbbVie maintains no significant remaining patent cliff through the end of the current decade and maintains a deep pipeline with multiple potential blockbuster candidates, providing medium-term growth catalysts beyond its current dividend yield of 2.7%.
- • Englander's portfolio concentration is notable: approximately 15% of Millennium's $240 billion in assets under management is invested in just 10 stocks, reflecting high conviction in select positions.
Summary
Israel Englander, the founder and head of Millennium Management, a major hedge fund with $240 billion in assets under management, has significantly increased his firm's exposure to two dividend-paying stocks during the second quarter of 2026. Millennium more than doubled its stakes in both AbbVie, a diversified pharmaceutical company, and Costco, a membership-based retail giant. These moves reflect Englander's confidence in the near-term and medium-term prospects of both companies, particularly given his track record of delivering strong returns over multiple decades.
AbbVie faces a complex investment narrative that recent portfolio moves suggest Englander believes is underappreciated by the market. The pharmaceutical company has historically contended with patent cliff pressures and clinical setbacks that have constrained share price performance. However, the company's two key growth pillars—the immunology medicines Skyrizi and Rinvoq—are delivering substantially faster revenue growth than the company's overall top line. In the second quarter, AbbVie reported revenue growth of 10.2% year-over-year, reaching approximately $17 billion. Critically, neither Skyrizi nor Rinvoq will face patent expiration until the next decade, ensuring continued revenue contribution and market exclusivity for years to come.
Beyond its current product portfolio, AbbVie's risk profile has improved materially. The company faces no remaining significant patent cliff through the end of the current decade, eliminating a historically destabilizing factor for pharmaceutical valuations. Additionally, AbbVie maintains a deep development pipeline containing multiple candidates with blockbuster potential, providing additional growth catalysts beyond its existing marketed medicines. The company's dividend yield of 2.7% provides current income while the underlying business executes on pipeline advancement and revenue growth.
Englander's concentration strategy underscores his conviction in high-quality assets. Approximately 15% of Millennium's $240 billion portfolio is deployed across just 10 stocks, a significant concentration for a firm of this scale. The decision to more than double positions in both AbbVie and Costco during Q2 demonstrates that Englander and his team believe both securities offer compelling risk-adjusted returns relative to broader equity market alternatives.
AbbVie faces a complex investment narrative that recent portfolio moves suggest Englander believes is underappreciated by the market. The pharmaceutical company has historically contended with patent cliff pressures and clinical setbacks that have constrained share price performance. However, the company's two key growth pillars—the immunology medicines Skyrizi and Rinvoq—are delivering substantially faster revenue growth than the company's overall top line. In the second quarter, AbbVie reported revenue growth of 10.2% year-over-year, reaching approximately $17 billion. Critically, neither Skyrizi nor Rinvoq will face patent expiration until the next decade, ensuring continued revenue contribution and market exclusivity for years to come.
Beyond its current product portfolio, AbbVie's risk profile has improved materially. The company faces no remaining significant patent cliff through the end of the current decade, eliminating a historically destabilizing factor for pharmaceutical valuations. Additionally, AbbVie maintains a deep development pipeline containing multiple candidates with blockbuster potential, providing additional growth catalysts beyond its existing marketed medicines. The company's dividend yield of 2.7% provides current income while the underlying business executes on pipeline advancement and revenue growth.
Englander's concentration strategy underscores his conviction in high-quality assets. Approximately 15% of Millennium's $240 billion portfolio is deployed across just 10 stocks, a significant concentration for a firm of this scale. The decision to more than double positions in both AbbVie and Costco during Q2 demonstrates that Englander and his team believe both securities offer compelling risk-adjusted returns relative to broader equity market alternatives.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.